Rebecca Chambers Veracyte, Inc. (VCYT) insider trading activity

Rebecca Chambers is Chief Financial Officer of VERACYTE, INC.. Currently has a direct ownership of 113,699 shares of VCYT, which is worth approximately $3.82 Million. The most recent transaction as insider was on Mar 02, 2025, when has been sold 11,070 shares (Common Stock) at a price of $34.76 per share, resulting in proceeds of $384,793. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 114K

0.3% 3M change

34.21% 12M change

Total Value Held $3.82 Million

Rebecca Chambers Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Mar 02 2025	SELL Payment of exercise price or tax liability	$384,793 $34.76 p/Share	11,070 Reduced 8.87%	113,699 Common Stock
Feb 27 2025	SELL Payment of exercise price or tax liability	$403,068 $33.84 p/Share	11,911 Reduced 8.71%	124,769 Common Stock
Feb 27 2025	BUY Grant, award, or other acquisition	-	23,170 Added 14.49%	136,680 Common Stock
Feb 03 2025	SELL Open market or private sale	$23,108 $43.85 p/Share	527 Reduced 0.46%	113,510 Common Stock
Dec 03 2024	SELL Open market or private sale	$302,610 $43.23 p/Share	7,000 Reduced 5.78%	114,037 Common Stock
Dec 02 2024	SELL Payment of exercise price or tax liability	$152,831 $44.12 p/Share	3,464 Reduced 2.78%	121,037 Common Stock
Nov 12 2024	SELL Open market or private sale	$585,643 $38.34 p/Share	15,275 Reduced 10.93%	124,501 Common Stock
Sep 02 2024	SELL Payment of exercise price or tax liability	$109,289 $31.55 p/Share	3,464 Reduced 2.42%	139,776 Common Stock
Jun 02 2024	SELL Payment of exercise price or tax liability	$71,836 $20.75 p/Share	3,462 Reduced 2.36%	143,240 Common Stock
Mar 15 2024	SELL Payment of exercise price or tax liability	$46,187 $21.1 p/Share	2,189 Reduced 1.47%	146,702 Common Stock
Mar 15 2024	BUY Grant, award, or other acquisition	-	4,318 Added 2.82%	148,891 Common Stock
Mar 06 2024	BUY Grant, award, or other acquisition	-	59,856 Added 29.28%	144,573 Common Stock
Mar 02 2024	SELL Payment of exercise price or tax liability	$146,688 $24.0 p/Share	6,112 Reduced 6.73%	84,717 Common Stock
Dec 02 2023	SELL Payment of exercise price or tax liability	$47,772 $26.54 p/Share	1,800 Reduced 1.94%	90,829 Common Stock
Sep 02 2023	SELL Payment of exercise price or tax liability	$97,508 $26.7 p/Share	3,652 Reduced 3.79%	92,629 Common Stock
Jun 02 2023	SELL Payment of exercise price or tax liability	$31,609 $26.72 p/Share	1,183 Reduced 1.22%	95,754 Common Stock
Mar 06 2023	BUY Grant, award, or other acquisition	-	26,014 Added 21.16%	96,937 Common Stock
Mar 02 2023	SELL Payment of exercise price or tax liability	$65,696 $24.1 p/Share	2,726 Reduced 3.7%	70,923 Common Stock
Dec 02 2022	SELL Payment of exercise price or tax liability	$21,417 $29.14 p/Share	735 Reduced 1.0%	72,998 Common Stock
Sep 02 2022	SELL Payment of exercise price or tax liability	$57,981 $19.18 p/Share	3,023 Reduced 3.94%	73,733 Common Stock
Aug 05 2022	BUY Grant, award, or other acquisition	-	21,404 Added 21.81%	76,756 Common Stock
Mar 03 2022	BUY Grant, award, or other acquisition	-	20,728 Added 27.47%	54,728 Common Stock
Jul 19 2021	BUY Grant, award, or other acquisition	-	34,000 Added 50.0%	34,000 Common Stock

Also insider at

Outset Medical, Inc. Healthcare

Chief Financial Officer

NARI

Inari Medical, Inc. Healthcare

Director